The role of PPARs in NASH fibrogenesis
Prof G. Szabo reviews the learnings about alcohol consumption and liver disease that were presented during the Liver meeting 2019 in Boston.
I think there are going to be many take-home messages…
Prof Szabo Discusses the Progresses of the Quest of Biomarkers in NASH
Gyongyi Szabo, MD, PhD is the Worcester Foundation for Biomedical Research Endowed Chair, Professor and Vice Chair of Medicine and Associate Provost at the University of Massachusetts Medical School. Dr. Szabo is an internationally recognized leader in the field of liver immunology and inflammation. Her clinical investigations focus on alcoholic hepatitis, non-alcoholic fatty liver disease and viral hepatitis.
She is the lead investigator on an NIH-supported multicenter clinical trial in alcoholic hepatitis. Her laboratory studies the cellular and molecular mechanisms of inflammation and innate immunity in liver injury to identify therapeutic targets in liver diseases including non-alcoholic liver disease and NASH. Her investigations recently revealed the importance of micro-RNAs and extracellular vesicles in liver diseases.
Dr. Szabo’s is member of the Hungarian Academy of Sciences, and fellow of the AASLD, AGA and the American College of Physicians (ACP). Dr. Szabo serves on advisory boards of several federal agencies and leading academic institutions. Dr. Szabo served on the Governing Board and as President of the American Association for the Study of Liver Diseases (AASLD) in 2015 and she the inaugural Editor-in-Chief of Hepatology Communications.